Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Fyfe-chaired medicinal cannabis firm gets $6 mln investment

Fyfe-chaired medicinal cannabis firm gets $6 mln investment

By Rebecca Howard

April 26 (BusinessDesk) - Pure Cann New Zealand, which counts former Air New Zealand boss Rob Fyfe as its executive chair, has secured $6 million from Australia's Cann Group for a 20 percent stake in the local medicinal cannabis company.

The investment will be made over stages with the initial 10 percent to be completed on or before Aug. 30 and a further 10 percent when New Zealand regulations come into force and Pure Cann's board approves the construction of its commercial cultivation facility.

The New Zealand government anticipates introducing new regulations, licensing requirements and quality standards governing medicinal cannabis usage by the end of this calendar year.

ASX-listed Cann Group has the option to increase its position to 30 percent.

Fyfe, currently Pure Cann's second largest shareholder with a 25.2 percent stake, said the move is a "pivotal moment for New Zealand's medicinal cannabis industry."

The strategic investment and a technical services agreement - which allows for mutual sharing of intellectual property - "ensure that Pure Cann is now fully funded and, more importantly, allows us to leverage the cultivation, production and technical leadership of Cann Group," the former Icebreaker chair said.

The move lets the two companies work together to "capitalise on the growing demand for medicinal cannabis in New Zealand and explore potential export opportunities as Pure Cann develops its own proposed cultivation and production facilities," said Cann Group chief executive Peter Crock.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

Cann Group has established research and cultivation facilities in Melbourne and is looking to provide access to medicinal cannabis for Australian patients. Aurora Cannabis, one of Canada's largest listed medicinal cannabis companies, owns 22.9 percent of the Australian firm.

"Pure Cann is proposing to develop a range of organic medicinal cannabis products to serve patient needs in New Zealand and potential export markets," Crock said. "We are confident that Pure Cann will be able to leverage New Zealand's global reputation for development world leading premium and natural products."

(BusinessDesk)

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.